文献类型：期刊文献

中文题名：安神二号胶囊对慢性精神分裂症患者认知和社会功能的影响

英文题名：Study on Effects of No.2 AnShen Capsule on Cognitive and Social Function of Patients with Chronic Schizophrenia

作者：石洲宝[1];陈长浩[1];高娜[1];刘成松[1];刘敏科[1];黄生辉[1]

第一作者：石洲宝

机构：[1]甘肃中医学院附属医院,甘肃兰州730020

第一机构：甘肃中医药大学第二附属医院

年份：2015

卷号：28

期号：4

起止页码：1

中文期刊名：西部中医药

外文期刊名：Western Journal of Traditional Chinese Medicine

收录：CSTPCD

基金：甘肃省中医药科研项目(编号GZK-2013-33)

语种：中文

中文关键词：精神分裂症,慢性;安神胶囊;维思通;认知;社会功能

外文关键词：schizophrenia;chronic;Anshencapsule;cognition;social function

摘要：目的：探讨安神胶囊对慢性精神分裂症患者认知和社会功能的影响。方法：采用随机、双盲、双模拟试验方法，将200例患者随机分为观察组和对照组各100例，观察组口服安神胶囊，4粒/次，3次/d；对照组口服维思通，1～1.5 mg/d，2组均治疗8周。于基线和治疗8周末分别计算认知功能评定量表（WCST）评分、社会功能量表（SDSS）评分；于治疗前，治疗第2、4、6、8周分别计算阳性症状量表（SAPS）评分、阴性症状量表（SANS）评分、临床总体印象量表（CGI）评分，并以药物副反应量表（TESS）评定药物的副反应。结果：治疗第8周末，2组SAPS、SANS及SDSS评分均较基线降低，WCST指标中除了观察组持续应答数外均获改善，差异均有统计学意义（P＜0.05）；观察组SANS、SAPS评分的降低较对照组更为明显（P＜0.05）。安神胶囊组WCST各指标改善较对照组明显（P＜0.05）。 SANA有效率、CGI临床进步率观察组分别为79.9%、86.6%，对照组分别为85.3%、89.3%,2组比较差异均无统计学意义（P＞0.05）。结论：安神胶囊对慢性精神分裂症患者认知和社会功能的改善更为有效，且副反应小。
To explore the effects ofAnshencapsule on cognitive and social function of cases with chronic schizophrenia. Methods： All 200 cases were divided into the observation group and the control group, with 100 cases in each. The observation group was treated by orally takingAnShencapsule, with four pills per time and three times per day, and the control group were given risperidone （1～1.5 mg/d）. Treatment last for eight weeks in two groups. Scores of WCST and SDSS were calculated from the baseline and the end of 8 th week after treatment; scores of SAPS, SANS, CGI and TESS WERE calculated before the treatment and at 2 th, 4 th, 6 th and 8 th week during treatment. Results： At the end of 8th week, scores of SAPS, SANS and SDSS in two groups decreased when compared to that of the baseline. All indicators in WCST got improvement except constant answering, which indi-cated that there was statistical significance （P〈0.05）. And the decrease of scores of SANS and SAPS were much more obvious when compared to that of the control group. Compared to the control group, indicators ofAnshencap-sule group got better improvement（P〈0.05）. Efficiency of SANA and of CGI were 79.9%, 86.6% and 85.3%, 89.3% respectively, which showed no statistical significance between two groups （P〉0.05）. Conclusion：Anshencapsule is effective in improving cognitive and social function of patients with chronic schizophrenia and has little side effects.